Lupin share news, announcements and annual reports
NSE: LUPINBSE: 500257Pharmaceuticals & BiotechnologyMid Cap
Lupin Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1993 on BSE, Sep 2001 on NSE
Last close ₹1,989.90up ₹17.20 (0.87%)BSE ₹1,998.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,972.70.
29 Oct: open ₹1,977.40, high ₹1,999.60, low ₹1,962.30
52-week range of traded prices to 29 Oct 2026
₹1,892.90Low, 23 Oct 2026₹2,529.50High, 16 Jul 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹90,996 Cr105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.46
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 14.95
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.05
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 30.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 28.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,81,45154.5% delivered
Lupin disputes and clarifications
36 filed, newest first.
Apr 2026
17 Apr · Legal
Feb 2026
10 Feb · Legal
Apr 2025
16 Apr · Legal
Feb 2025
6 Feb · Legal
3 Feb · Legal
Jul 2024
Jun 2024
26 Jun · Legal
Exchange has sought clarification from Lupin Limited with respect to announcement dated 06-May-2024, regarding appointment of Mr. Alfonso Zulueta as Independent Director of the company w.e.f. May 06, 2024. On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. The response of the Company is awaited.
May 2019
13 May · Legal
Exchange has sought clarification from the Company with respect to news item captioned- titled "Pharma stocks bleed as US states file lawsuit against generic drug firms". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company was aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Apr 2019
Feb 2019
Jun 2018
4 Jun · Legal
Exchange has sought clarification from Lupin Limited with respect to announcement dated 04-Jun-2018, regarding " Lupin Limited has informed the Exchange regarding the Registrar & Share Transfer Agent Update". On basis of above the Company is required to clarify following: 1. Reason for appointment or discontinuation; The response of the Company is awaited.
May 2017
9 May · Legal
Exchange has sought clarification from the Company with respect to news item captioned "US FDA issues 8 observations for Aurangabad plant." In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Apr 2017
28 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned "Lupin's Goa plant receives adverse FDA Observations". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.5 Apr · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned "Lupin's arm to pay damages to Bayer". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Feb 2016
25 Feb · Legal
Exchange had sought clarification from Lupin Limited with respect to recent news item captioned "Lupin Plans to Step Up Japanese Play". The Company, has vide email dated February 25, 2016 stated 'With reference to the media report titled, Lupin Plans to Step Up Japanese Play , we wish to state that Kyowa Pharmaceutical Industry Co., Ltd., Japan, ( Kyowa ), wholly-owned subsidiary of the Company has a Plant at Sanda, Japan.In order to meet the rapidly growing demand of generics, the Kyowa Board has proposed the setting-up of a 2 Bn. Tablets capacity Plant at Tottori, Japan which would be designed to efficiently handle mass volume products and provide flexibility in allowing easy future expansion'25 Feb · Legal
Exchange has sought clarification from Lupin Limited with respect to recent news item captioned "Lupin plans to step up Japanese play . In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under regulation 30 of Listing regulations. The response from the Company is awaited.
Jul 2015
23 Jul · Legal
Exchange has sought clarification from Lupin Limited with respect to recent news item captioned "Lupin acquires Gavis for $880mn". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Mar 2015
16 Mar · Legal
Exchange has sought clarification from Lupin Limited with respect to announcement dated March 16, 2015 that "Lupin Completes Acquisition of Pharma Dynamics, South Africa" On basis of above the Company is required to clarify following: a) Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof; b) Whether the acquisition would fall within related party transactions? If yes, whether the same is done at arm s length; c) Estimated cost of acquisition or the price at which the shares are acquired; d) Nature of consideration - whether cash consideration or share swap and details of the same; The response of the Company is awaited.
Feb 2015
4 Feb · Legal
Exchange had sought clarification from Lupin Limited with respect to a news item captioned "Lupin eyes small-sizes assets in Russian market". The Company has clarified that "In its day-to-day operations, the Company actively explores opportunities for organic and inorganic growth including overseas acquisitions. We wish to state that the Company shall promptly inform the Exchanges once any such proposal is considered and duly approved by the Board of Directors".4 Feb · Legal
Exchange has sought clarification from Lupin Limited with respect to recent news item captioned "Lupin eyes small-sizes assets in Russian market". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Jan 2015
29 Jan · Legal
Exchange has sought clarification from Lupin Limited with respect to recent news item captioned "Lupin gets nod to raise FII limit to 49% . In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
15 Dec · Legal
Exchange had sought clarification from Lupin Limited with respect to recent news item captioned "Scouting for Acquisitions in India: Lupin". In this regard, the Company, vide email dated December 15, 2014 has clarified that: "We wish to state that in its day-to-day operations, the Company actively explores opportunities for organic and inorganic growth including acquisitions. We wish to add that the Company shall promptly inform the Exchanges once any such proposal is duly approved by the Board".15 Dec · Legal
Exchange has sought clarification from Lupin Limited with respect to recent news item captioned Scouting for Acquisitions in India: Lupin. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: "a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement". The response from the Company is awaited.12 Dec · Legal
Exchange had sought clarification from Lupin Limited with respect to a news item captioned "Germany bans 80 generic drugs for insufficient trials". The Company has clarified that "GVK Biosciences (GVK), Hyderabad based Clinical Research Organisation conducts Bio-equivalence (BE) studies for various pharma companies across the globe. The Federal Institute for Drugs and Medical Devices (BfArM), German Regulator banned 80 generic medicines on the ground of deficiencies in the clinical trials/ bioequivalence studies conducted by GVK. Cefpodoxime, a cephalosporin antibiotic marketed by Hormosan Pharma GmbH, Germany, wholly-owned subsidiary of Lupin Limited was banned by BfArM as its BE studies were conducted at GVK. We wish to state that the sale of efpodoxime 200mg tablets in Germany is negligible and its banning will not have any material impact on the operations of the Company. As the above would not have any bearing on the operations/performance of the Company, was not disclosed to the Stock Exchanges".11 Dec · Legal
Exchange has sought clarification from Lupin Limited with respect to recent news item captioned "Germany bans 80 generic drugs for insufficient trials". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2014
27 Oct · Legal
Exchange had sought clarification from Lupin Limited with respect to a news item captioned "Lupin scouts for acquisition opportunities in US market". The Company has clarified that "We continue to evaluate opportunities and going forward acquisitions in the US would have to satisfy our multiple aspirations of creating a meaningful speciality business, bolstering our existing brands business and acquiring technological capabilities that we would like to work on", Lupin CFO S Ramesh said. "The company continues to be on the lookout for meaningful targets, be it brands or technology companies, in inhalation, complex injectables and skin diseases segments", he added. Terming the US as a high growth market for the company, the Mumbai-based firm said it aims to grow at around 25 per cent in the world's largest drug market. "For Lupin, the US is a high growth market and the major contributor to the company's overall revenues and profitability. We don't give guidances but if the past is prescriptive of the future we would aim to maintain our current growth momentum for the US market - between 20-25 per cent", Ramesh said. We wish to state that the Company in its ordinary course of business continuously explores and evaluates business opportunities and the comments of Mr. Ramesh are general in nature and do not allude to any specific acquisition opportunity. We wish to add that a major part of the article deals with historical data and facts which are in public domain. As has been our track record, we remain committed to respecting disclosure norms and upholding good corporate governance practices.22 Oct · Legal
Exchange has sought clarification from Lupin Limited with respect to recent news item captioned "Lupin scouts for acquisition opportunities in US market". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Jul 2014
31 Jul · Legal
Exchange had sought clarification from Lupin Limited with respect to a news item captioned "Debt - free Lupin is Ready for Big Acquisition : CEO". The Company has clarified that "1) Comments on the news article: Ms. Vinita Gupta's comments about the Company being debt-free were based on the unaudited financial results for the quarter ended June 30, 2014, which were taken on record by the Board of Directors of Lupin Ltd. at its meeting held on July 30, 2014, conveyed to the Stock Exchanges and published in the newspapers. We wish to state that numbers quoted by Ms. Vinita in the news item forms part of the Press Release which was sent to the Stock Exchanges along with the said results. 2) Material impact of the news article on the Company: In its day-to-day operations, the Company actively explores opportunities for organic and inorganic growth including overseas acquisitions. The Company shall promptly inform the Exchanges once an acquisition is duly approved by the Board. 3) Relevant disclosure in this context: The news item states that the Company refused to comment. This is because, the Company does not comment on market rumours and speculations".
May 2014
21 May · Legal
Exchange had sought clarification from Lupin Limited with respect to news item captioned "Venus ties up with Lupin to sell antibiotic drug in Oz.". The Company has clarified that "Lupin Limited has not received an official confirmation from Therapeutic Goods Administration (TGA) of Australia. We wish to further state that it is a routine transaction and does not have any material impact on the operations/profitability of the Company".